According to the latest GLOBOCAN data released in 2024, esophageal cancer ranks the 11th in global cancer incidence and represents the 7th leading cause of cancer-related mortality worldwide. In 2022, there were approximately 511000 newly diagnosed cases of esophageal cancer and 445000 deaths globally. On February 28, 2025, the National Comprehensive Cancer Network (NCCN) published updated clinical practice guidelines for esophageal and esophagogastric junction cancers (version 1.2025). This article provides a comprehensive analysis of the major diagnostic and therapeutic updates in the guidelines compared to the version 5.2024, encompassing key domains including screening stratification protocols, perioperative treatment optimization strategies, dynamic efficacy evaluation systems, molecular subtyping-guided therapeutic approaches, and immunotherapy expansion algorithms. The findings aim to provide references for esophageal cancer treatment in China.
Giant cell tumor of bone (GCTB), osteosarcoma, and Ewing sarcoma represent the most characteristic primary bone neoplasms, and optimization of their diagnostic and therapeutic strategies remains a research priority in the field of bone and soft tissue oncology. The National Comprehensive Cancer Network (NCCN) released the Clinical Practice Guidelines in Bone Cancer (Version 2.2026), introducing key evidence-based updates spanning equivalent biological therapy alternatives, perioperative chemotherapy conceptual restructuring, expanded management strategies for recurrent/progressive disease, refined molecular diagnostic protocols, fertility preservation, and standardization of rare subtype treatment. This article systematically interprets the revision highlights of this guideline, integrates recent high-level clinical research evidence, analyzes its evidence-based foundation and clinical translation pathway, and compares it with relevant domestic diagnostic and therapeutic standards to provide academic reference for multidisciplinary standardized management of bone tumors in China.